Abstract
The treatment of patients with vulvar cancer remains challenging for gynecologic oncologists. Up to 30 % of the cases are diagnosed in a clinical condition of irresectability, and some kind of strategy has to be taken into account beyond surgery. In this regard, a common and standard definition is critical to maximize oncological results and minimize complications after treatments. Each patient treatment must be tailored individually according to their clinical and biological features and to the setting in which they are dealing with.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Benedet JL, Bender H, Jones 3rd H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–62.
Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018–22.
Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106–30.
Stroup AM, Harlan LC, Trimble EL. Demographic, clinical and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol. 2008;108:577–83.
Aragona AM, Cuneo NA, Soderini AH. Epidemiology of gynecological cancers. Scientific conference of the Oncology Hospital of Buenos Aires Marie Curie 80th anniversary. Autonomous City of Buenos Aires. 2011.
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.
Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumours. 7th ed. Oxford: Wiley- Blackwell; 2009.
Aragona AM, Soderini AH, Cuneo NA. Defining the concept of locally advanced squamous cell carcinoma of the vulva: a new perspective based on standardization of criteria and current evidence. J Gynecol Oncol. 2014;25(4):272–8.
Aragona AM, Cuneo NA, Soderini AH, Alcoba EB. An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: is tumor size significance being underrated? Gynecol Oncol. 2014;132(3):643–8. The concept of a new subgroup of risk, which allows a better stratification for treatment selection, has been introduced by the authors.
Benedetti-Panici P, Greggi S, Scambia G, et al. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol. 1993;50:49–53.
Belinson JL, Stewart JA, Richards AL, et al. Bleomycin, vincristine, mitomycin-C, and cisplatin in the management of gynecologic squamous cell carcinomas. Gynecol Oncol. 1985;20:387–93.
Wagenaar HC, Colombo N, Vergote I, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer Gynecol Oncol. 2001;81:348.
Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol. 2006;100:53–7.
Witteveen PO, Van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group). Ann Oncol. 2009;20:1511–6. 19.
Domingues AP, Mota F, Durao M, et al. Neoadjuvant chemotherapy in advanced vulvar cancer. Int J Gynecol Cancer. 2010;20:294–8.
Aragona AM, Cuneo N, Soderini AH, Alcoba E, Greco A, Reyes C, et al. Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study. Int J Gynecol Cancer. 2012;22(7):1258–63. The largest prospective study published to date regarding the topic. Neoadjuvant chemotherapy produced a considerable response rate >80% and the 5-year survival rate following surgery was >92%.
Reade CJ, Eiriksson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol. 2014;132(3):780–9.
Deppe G, Mert I, Winer IS. Management of squamous cell vulvar cancer: a review. J Obstet Gynaecol Res. 2014;40(5):1217–25.
Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol. 2007;104:636–41.
Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42(1):79–85.
De Hullu JA, Hollema H, Lolkema S, Boezen M, Boonstra H, Burger MP, et al. Vulvar carcinoma. The price of less radical surgery. Cancer. 1992;95(11):2331–8.
Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990;38(3):309–14.
Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986;68:733–40.
Parthasarathy A, CheungMK OK, Husain A, TengNN BJS, et al. The benefit of adjuvant radiation therapy in single node positive squamous cell vulvar carcinoma. Gynecol Oncol. 2006;103:1095–9.
Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally- advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):529–33. Pioneering GOG publication as for chemoradiation in vulvar cancer.
Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev. 2011;4:CD003752.
Bortolozzi G, Arnoletti E, Belloni C, et al. New integrated therapy in vulvar cancer. Proceedings of International Meeting of Gynecologic Oncology. 1985;420.
Strzinar V, Kocijan A, Kovacic J, et al. Adriamycin and bleomycin in treatment of advanced or recurrent squamous cell carcinoma of the vulva. Proceedings of International Meeting of Gynecologic Oncology. 1985;408:15Y19.
Itala J, Belardi G, Sardi J, et al. Poliquimioterapia neoadyuvante en el tratamiento del carcinoma invasor de la vulva. Revista de la Sociedad de Obstetricia y Ginecologı´a de Buenos Aires (SOGIBA). 1986;865:239Y245.
Shimizu Y, Hasumi K, Masubuchi K. Effective chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) for a patient with inoperable vulvar cancer. Gynecol Oncol. 1990;36:423Y427.
Sardi JE, Di Paola GR, et al. A possible new trend in the management of the carcinoma of the cervix uteri. Gyn Oncol. 1986;25:139.
Giaroli A, Sananes C, Sardi JE, Maya AG, Bastardas ML, Snaidas L, et al. Lymph node metastases in carcinoma of the cervix uteri: response to neoadjuvant chemotherapy and its impact on survival. Gynecol Oncol. 1990;39(1):34–7.
Sardi JE, Sananes C, Giaroli A, et al. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecologic Oncology. 1990;38:486–93.
Sardi J, Giaroli A, Sananes C, Rueda NG, Vighi S, Ferreira M, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management. International Journal of Gynecological Cancer. 1996;6(2):85–93.
Sardi J, Giaroli A, Sananes C, et al. Long term follow up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol. 1997;67:61–9.
Sananes C, Giaroli A, Soderini A, Guardado N, Sanaidas L, Bermúdez A, et al. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cérvix uteri: long-term follow up of a pilot study. Eur J Gynaecol Oncol. 1998;19(4):368–73.
Sardi S, Giaroli B, Ferreira S, Snaidas G, Anchezar Contreras O, Di P. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. International Journal of Gynecological Cancer. 1998;8(6):441–50.
Tierney J. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Eur J Cancer. 2003;39(17):2470–86. Review.
Francesco R, Flavia Z, Fabio M, Santiago C, Joel L, Antonino D. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol Oncol. 2014;25(1):22–9.
de Vulva C, Azcune. Guias para el diagnóstico, tratamiento y segimiento del cáncer ginecológico.Asociacion Argentina de Ginecología Oncológica. 2013. p. 13–32.
Acknowledgments
To Nicasio Cuneo, a great boss and better friend.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Gynecologic Cancers
Rights and permissions
About this article
Cite this article
Soderini, A., Aragona, A. & Reed, N. Advanced Vulvar Cancers: What are the Best Options for Treatment?. Curr Oncol Rep 18, 64 (2016). https://doi.org/10.1007/s11912-016-0545-6
Published:
DOI: https://doi.org/10.1007/s11912-016-0545-6